Ackermann 1988.

Methods	Study design: parallel RCT Study duration: not reported Study follow‐up: 3 to 12 months
Participants	Country: USA Setting: single centre (Florida) Inclusion criteria: adult (> 16 years) DD kidney transplant recipients (100%); financial resources for CSA therapy after discharge Number: treatment group (33); control group (33) Mean age ± SD (years): not reported Sex (M/F): treatment group (21/12); control group (23/12) Ethnicity (other/African American): treatment group (23/10); control group (21/12) Exclusion criteria: fluid overload (unresolved by dialysis); previous exposure to OKT3, pregnant or lactating women
Interventions	Treatment group OKT3: 5 mg/d IV for 14 days CSA: started day 11, target trough 300 to 500 ng/mL Control group CSA: twice daily started day 1 (unsure), target trough level 300 to 500 ng/mL Immunosuppression (both groups) AZA: 2.5 mg/kg (adjusted per WCC and kidney function) MP‐PRED: 2 g IV intra‐op then PRED 0.25 mg/kg/d
Outcomes	Death Graft loss Acute rejection DGF Infection Graft function
Notes	Outcomes reported for 3 months only as some patients only followed to 3 months at time of reporting (some but NOT all patients followed for 12 months) Funding source: "Supported by a grant from Othro Pharmaceutical Corp (Raritan, NJ)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Low risk	'Randomized by sealed envelope draw'
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Unblinded but not likely to influence most outcomes; may influence reporting of infections
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not certain if acute rejection was biopsy‐proven or clinically diagnosed
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patient outcome data reported
Selective reporting (reporting bias)	Low risk	All expected outcomes reported
Other bias	High risk	Grant from Ortho Pharmaceutical Corp (OKT3 manufacturer)